Allogene Therapeutics Inc (NASDAQ:ALLO) Major Shareholder Group Holdings (Sbs) Advis Tpg Sells 24,904 Shares

Share on StockTwits

Allogene Therapeutics Inc (NASDAQ:ALLO) major shareholder Group Holdings (Sbs) Advis Tpg sold 24,904 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $43.27, for a total transaction of $1,077,596.08. The sale was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Group Holdings (Sbs) Advis Tpg also recently made the following trade(s):

  • On Friday, June 26th, Group Holdings (Sbs) Advis Tpg sold 500 shares of Allogene Therapeutics stock. The shares were sold at an average price of $44.01, for a total transaction of $22,005.00.
  • On Wednesday, June 24th, Group Holdings (Sbs) Advis Tpg sold 15,269 shares of Allogene Therapeutics stock. The shares were sold at an average price of $43.93, for a total value of $670,767.17.
  • On Monday, June 22nd, Group Holdings (Sbs) Advis Tpg sold 172,425 shares of Allogene Therapeutics stock. The stock was sold at an average price of $42.83, for a total value of $7,384,962.75.
  • On Friday, June 19th, Group Holdings (Sbs) Advis Tpg sold 47,767 shares of Allogene Therapeutics stock. The stock was sold at an average price of $42.04, for a total value of $2,008,124.68.
  • On Wednesday, June 17th, Group Holdings (Sbs) Advis Tpg sold 87,319 shares of Allogene Therapeutics stock. The shares were sold at an average price of $42.18, for a total value of $3,683,115.42.
  • On Monday, June 15th, Group Holdings (Sbs) Advis Tpg sold 129,154 shares of Allogene Therapeutics stock. The shares were sold at an average price of $42.14, for a total value of $5,442,549.56.
  • On Wednesday, June 3rd, Group Holdings (Sbs) Advis Tpg sold 487,402 shares of Allogene Therapeutics stock. The stock was sold at an average price of $47.40, for a total transaction of $23,102,854.80.

ALLO stock opened at $41.86 on Wednesday. The company has a current ratio of 18.81, a quick ratio of 18.81 and a debt-to-equity ratio of 0.08. Allogene Therapeutics Inc has a 12-month low of $17.43 and a 12-month high of $55.00. The business’s fifty day moving average price is $44.31 and its 200 day moving average price is $29.73.

Allogene Therapeutics (NASDAQ:ALLO) last released its earnings results on Wednesday, May 6th. The company reported ($0.58) earnings per share for the quarter, meeting the consensus estimate of ($0.58). As a group, equities analysts anticipate that Allogene Therapeutics Inc will post -2.27 earnings per share for the current fiscal year.

Several brokerages recently issued reports on ALLO. Zacks Investment Research raised shares of Allogene Therapeutics from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a report on Thursday, April 2nd. Guggenheim raised Allogene Therapeutics from a “neutral” rating to a “buy” rating in a report on Friday, May 15th. ValuEngine cut Allogene Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 21st. BidaskClub downgraded Allogene Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 29th. Finally, SunTrust Banks upped their price objective on shares of Allogene Therapeutics from $32.00 to $50.00 and gave the company a “hold” rating in a report on Monday, June 8th. Six equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $45.21.

Institutional investors have recently bought and sold shares of the company. Stralem & Co. Inc. acquired a new stake in shares of Allogene Therapeutics in the first quarter valued at $32,000. Advisor Group Holdings Inc. purchased a new stake in shares of Allogene Therapeutics during the first quarter worth approximately $33,000. Quantbot Technologies LP acquired a new stake in Allogene Therapeutics in the fourth quarter valued at approximately $36,000. Great West Life Assurance Co. Can purchased a new position in Allogene Therapeutics in the fourth quarter worth approximately $42,000. Finally, Bourgeon Capital Management LLC lifted its position in shares of Allogene Therapeutics by 80.0% during the 1st quarter. Bourgeon Capital Management LLC now owns 2,250 shares of the company’s stock worth $44,000 after purchasing an additional 1,000 shares during the last quarter. 57.97% of the stock is currently owned by institutional investors and hedge funds.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.

See Also: What’s a Black Swan?

Insider Buying and Selling by Quarter for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Schroder Real Estate Investment Trst  Stock Crosses Below Two Hundred Day Moving Average of $43.15
Schroder Real Estate Investment Trst Stock Crosses Below Two Hundred Day Moving Average of $43.15
Picton Property Income  Share Price Passes Below 200 Day Moving Average of $81.72
Picton Property Income Share Price Passes Below 200 Day Moving Average of $81.72
UBS Group Analysts Give Siltronic  a €92.00 Price Target
UBS Group Analysts Give Siltronic a €92.00 Price Target
Nokia Oyj  PT Set at €4.50 by UBS Group
Nokia Oyj PT Set at €4.50 by UBS Group
Melrose Industries PLC  Receives Average Rating of “Buy” from Analysts
Melrose Industries PLC Receives Average Rating of “Buy” from Analysts
Trade Desk Inc  Receives Consensus Recommendation of “Buy” from Analysts
Trade Desk Inc Receives Consensus Recommendation of “Buy” from Analysts


© 2006-2020 Ticker Report